Recent Developments in Alpha-Glucosidase Inhibitors for Management of Type-2 Diabetes: An Update

Author(s): Bashir Usman, Neha Sharma, Saurabh Satija, Meenu Mehta, Manish Vyas, Gopal L. Khatik, Navneet Khurana*, Philip M. Hansbro, Kylie Williams, Kamal Dua*

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 23 , 2019


Become EABM
Become Reviewer
Call for Editor

Abstract:

The incidence of diabetes has increased globally in recent years and figures of diabetic patients were estimated to rise up to 642 million by 2040. The disorder is accompanied with various complications if not managed at the early stages, and interlinked high mortality rate and morbidity with time. Different classes of drugs are available for the management of type 2 diabetes but were having certain limitations of their safety. Alphaglucosidase is a family of enzyme originated from the pancreas which plays a role in the anabolism of 80-90% of carbohydrate consumed into glucose. This glucose is absorbed into the blood and results in frank postprandial hyperglycemia and worsens the conditions of diabetic patients which precipitate complications. Inhibition of these enzymes helps to prevent postprandial hyperglycemia and the formation of glycated end products. Alphaglucosidase inhibitors are reported to be more important in adequate control of type 2, but marketed drugs have various side effects, such as poor patient compliance and also expensive. This proves the needs for other class of drugs with better efficacy, safety, patient compliance and economic. In this review, we have emphasized the recent advances in the field of new alpha-glucosidase inhibitors with improved safety and pharmacological profile.

Keywords: Alpha-glucosidase, alpha-amylase, diabetes, hyperglycemia, insulin, pancreas.

[1]
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018; 14(2): 88-98.
[http://dx.doi.org/10.1038/nrendo.2017.151] [PMID: 29219149]
[2]
Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018; 138: 271-81.
[http://dx.doi.org/10.1016/j.diabres.2018.02.023] [PMID: 29496507]
[3]
Tripathi K. Essentials of Medical Pharmacology. 7th ed. Jaypee Brothers Medical Publishers (P) Ltd. 2013.
[4]
National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28(12): 1039-57.
[http://dx.doi.org/10.2337/diab.28.12.1039] [PMID: 510803]
[5]
Cameron F. Teenagers with diabetes--management challenges. Aust Fam Physician 2006; 35(6): 386-90.
[PMID: 16751852]
[6]
Blonde L. Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. Am J Med 2010; 123(3)(Suppl.): S12-8.
[http://dx.doi.org/10.1016/j.amjmed.2009.12.005] [PMID: 20206727]
[7]
Keshri U, Satish C, Janardan S. Antidiabetic efficacy of ethanolic extract of holarrhena antidysenterica seeds in streptozotocin – induced diabetic rats and its influence on certain biochemical parameters. JDDT 2012; 2: 159-62.
[8]
Rossetti L. Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus. Clin Invest Med 1995; 18(4): 255-60.
[PMID: 8549010]
[9]
Mohammad Ashraf Ganie. Suman Kotwal. Recent advances in the management of diabetes mellitus. JIMSA 2012; 25: 317-23.
[10]
Kumar RV, Sinha VR. Newer insights into the drug delivery approaches of α-glucosidase inhibitors. Expert Opin Drug Deliv 2012; 9(4): 403-16.
[http://dx.doi.org/10.1517/17425247.2012.663080] [PMID: 22364261]
[11]
Ta S. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37(Suppl. 1): S81-90.
[http://dx.doi.org/10.2337/dc14-S081] [PMID: 24357215]
[12]
Inzucchi SE, Bergenstal RM, Buse JB, et al. American Diabetes Association (ADA) European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35(6): 1364-79.
[http://dx.doi.org/10.2337/dc12-0413] [PMID: 22517736]
[13]
Bischoff H. Pharmacology of alpha-glucosidase inhibition. Eur J Clin Invest 1994; 24(Suppl. 3): 3-10.
[PMID: 8001624]
[14]
Subramanian R, Asmawi MZ, Sadikun A. In vitro α-glucosidase and α-amylase enzyme inhibitory effects of Andrographis paniculata extract and andrographolide. Acta Biochim Pol 2008; 55(2): 391-8.
[PMID: 18511986]
[15]
Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 2005; 52(4): 313-20.
[http://dx.doi.org/10.1016/j.phrs.2005.05.004] [PMID: 15979893]
[16]
Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 2014; 18(1): 1-14.
[http://dx.doi.org/10.4196/kjpp.2014.18.1.1] [PMID: 24634591]
[17]
Thomas MC. Glycemic exposure, glycemic control, and metabolic karma in diabetic complications. Adv Chronic Kidney Dis 2014; 21(3): 311-7.
[http://dx.doi.org/10.1053/j.ackd.2014.03.004] [PMID: 24780460]
[18]
Alcubierre N, Rubinat E, Traveset A, et al. A prospective cross-sectional study on quality of life and treatment satisfaction in type 2 diabetic patients with retinopathy without other major late diabetic complications. Health Qual Life Outcomes 2014; 12: 131.
[http://dx.doi.org/10.1186/s12955-014-0131-2] [PMID: 25138117]
[19]
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52(1): 102-10.
[http://dx.doi.org/10.2337/diabetes.52.1.102] [PMID: 12502499]
[20]
Röder PV, Wu B, Liu Y, Han W. Pancreatic regulation of glucose homeostasis. Exp Mol Med 2016; 48e219
[http://dx.doi.org/10.1038/emm.2016.6] [PMID: 26964835]
[21]
Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46(1): 3-19.
[http://dx.doi.org/10.1007/s00125-002-1009-0] [PMID: 12637977]
[22]
Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014; 383(9922): 1068-83.
[http://dx.doi.org/10.1016/S0140-6736(13)62154-6] [PMID: 24315620]
[23]
Codario RA. Pathophysiology of type-2 diabetes Current Clin Prac. Totowa, NJ: Humana Press 2011; 2: pp. 1-14.
[http://dx.doi.org/10.1007/978-1-60327-441-8_1]
[24]
Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011; 378(9786): 169-81.
[http://dx.doi.org/10.1016/S0140-6736(11)60614-4] [PMID: 21705072]
[25]
Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clin Belg 2003; 58(6): 335-41.
[http://dx.doi.org/10.1179/acb.2003.58.6.001] [PMID: 15068125]
[26]
D’Adamo E, Caprio S. Type 2 diabetes in youth: epidemiology and pathophysiology. Diabetes Care 2011; 34(Suppl. 2): S161-5.
[http://dx.doi.org/10.2337/dc11-s212] [PMID: 21525449]
[27]
Apovian CM, Okemah J, O’Neil PM. Body weight considerations in the management of type 2 diabetes. Adv Ther 2019; 36(1): 44-58.
[http://dx.doi.org/10.1007/s12325-018-0824-8] [PMID: 30465123]
[28]
Chaudhury A, Duvoor C, Reddy Dendi VS, et al. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne) 2017; 8: 6.
[http://dx.doi.org/10.3389/fendo.2017.00006] [PMID: 28167928]
[29]
Punthakee Z, Goldenberg R, Katz P. Diabetes Canada Clinical Practice Guidelines Expert Committee. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes 2018; 42(Suppl. 1): S10-5.
[http://dx.doi.org/10.1016/j.jcjd.2017.10.003] [PMID: 29650080]
[30]
Zhou X, Pang Z, Gao W, et al. Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao, China. Diabetes Care 2010; 33(3): 545-50.
[http://dx.doi.org/10.2337/dc09-1410] [PMID: 20007941]
[31]
International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32(7): 1327-34.
[http://dx.doi.org/10.2337/dc09-9033] [PMID: 19502545]
[32]
Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci 2014; 11(11): 1185-200.
[http://dx.doi.org/10.7150/ijms.10001] [PMID: 25249787]
[33]
Scheen AJ. Investigational insulin secretagogues for type 2 diabetes. Expert Opin Investig Drugs 2016; 25(4): 405-22.
[http://dx.doi.org/10.1517/13543784.2016.1152260] [PMID: 26881467]
[34]
Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32(15): 1900-8.
[http://dx.doi.org/10.1093/eurheartj/ehr077] [PMID: 21471135]
[35]
Monami M, Luzzi C, Lamanna C, et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006; 22(6): 477-82.
[http://dx.doi.org/10.1002/dmrr.642] [PMID: 16634115]
[36]
Obale B, Banerjee M. Safety and Efficacy of Meglitinides in Combination with GLP-1 Analogues-A Case Series. J Endocrinol Thyroid Res 2017; 1: 4-6.
[37]
Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 2016; 12(10): 566-92.
[http://dx.doi.org/10.1038/nrendo.2016.86] [PMID: 27339889]
[38]
Kim HI, Ahn YH. Role of peroxisome proliferator-activated receptor-γ in the glucose-sensing apparatus of liver and β-cells. Diabetes 2004; 53(Suppl. 1): S60-5.
[http://dx.doi.org/10.2337/diabetes.53.2007.S60] [PMID: 14749267]
[39]
Bermúdez V, Finol F, Parra N, et al. PPAR-γ agonists and their role in type 2 diabetes mellitus management. Am J Ther 2010; 17(3): 274-83.
[http://dx.doi.org/10.1097/MJT.0b013e3181c08081] [PMID: 20216208]
[40]
Harris F, Pierpoint L. Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent. Med Res Rev 2012; 32(6): 1292-327.
[http://dx.doi.org/10.1002/med.20251] [PMID: 21793017]
[41]
Hinnen D, Nielsen LL, Waninger A, Kushner P. Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes. J Am Board Fam Med 2006; 19(6): 612-20.
[http://dx.doi.org/10.3122/jabfm.19.6.612] [PMID: 17090794]
[42]
Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29(1): 46-52.
[http://dx.doi.org/10.1007/BF02427280] [PMID: 3514343]
[43]
Mikhail N. Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease. Postgrad Med 2012; 124(4): 138-44.
[http://dx.doi.org/10.3810/pgm.2012.07.2575] [PMID: 22913902]
[44]
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-53.
[http://dx.doi.org/10.2337/diacare.27.5.1047] [PMID: 15111519]
[45]
Satyanarayana U, Chakrapani U. Essentials of biochemistry. 3rd ed. Kolkata: Books and Allied (P) Ltd. 2007.
[46]
Hossain MA, Pervin R. Current Antidiabetic Drugs: Review of Their Efficacy and Safety. 2nd ed. InNutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome 2018; pp. 455-73.
[http://dx.doi.org/10.1016/B978-0-12-812019-4.00034-9]
[47]
Dhatariya K. Diabetes: the place of new therapies. Ther Adv Endocrinol Metab 2018; 102042018818807599
[PMID: 30800266]
[48]
Chan CW, Yu CL, Lin JC, et al. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study. Cardiovasc Diabetol 2018; 17(1): 20.
[http://dx.doi.org/10.1186/s12933-018-0663-6] [PMID: 29368615]
[49]
Laskar J, Bhattacharjee K, Sengupta M, Choudhury Y. Anti-diabetic drugs: cure or risk factors for cancer? Pathol Oncol Res 2018; 24(4): 745-55.
[http://dx.doi.org/10.1007/s12253-018-0402-z] [PMID: 29536373]
[50]
Nalawade ML, Patil RS, Bavkar LN, Rooge SB, Haldavnekar VS, Arvindekar AU. Early metabolic changes in the gut leads to higher expression of intestinal alpha glucosidase and thereby causes enhanced postprandial spikes. Life Sci 2019; 218: 8-15.
[http://dx.doi.org/10.1016/j.lfs.2018.12.025] [PMID: 30553872]
[51]
Campbell LK, White JR, Campbell RK. Acarbose: its role in the treatment of diabetes mellitus. Ann Pharmacother 1996; 30(11): 1255-62.
[http://dx.doi.org/10.1177/106002809603001110] [PMID: 8913408]
[52]
Yang W, Liu J, Shan Z, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol 2014; 2(1): 46-55.
[http://dx.doi.org/10.1016/S2213-8587(13)70021-4] [PMID: 24622668]
[53]
Gao X, Cai X, Yang W, Chen Y, Han X, Ji L. Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations. J Diabetes Investig 2018; 9(2): 321-31.
[http://dx.doi.org/10.1111/jdi.12711] [PMID: 28685995]
[54]
Dabhi AS, Bhatt NR, Shah MJ. Voglibose: an alpha glucosidase inhibitor. J Clin Diagn Res 2013; 7(12): 3023-7.
[PMID: 24551718]
[55]
Kaku K. Efficacy of voglibose in type 2 diabetes. Expert Opin Pharmacother 2014; 15(8): 1181-90.
[http://dx.doi.org/10.1517/14656566.2014.918956] [PMID: 24798092]
[56]
Konya H, Katsuno T, Tsunoda T, et al. Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2013; 6: 317-25.
[http://dx.doi.org/10.2147/DMSO.S36046] [PMID: 24039439]
[57]
Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009; 373(9675): 1607-14.
[http://dx.doi.org/10.1016/S0140-6736(09)60222-1] [PMID: 19395079]
[58]
Negishi M, Shimomura K, Proks P, Shimomura Y, Mori M. Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients. Br J Clin Pharmacol 2008; 66(2): 318-9.
[http://dx.doi.org/10.1111/j.1365-2125.2008.03216.x] [PMID: 18507653]
[59]
Oh TJ, Yu JM, Min KW, et al. Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. Diabetes Metab J 2018; 42: 1-11.
[PMID: 30604594]
[60]
Vichayanrat A, Ploybutr S, Tunlakit M, Watanakejorn P. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract 2002; 55(2): 99-103.
[http://dx.doi.org/10.1016/S0168-8227(01)00286-8] [PMID: 11796175]
[61]
Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs 2000; 59(3): 521-49.
[http://dx.doi.org/10.2165/00003495-200059030-00012] [PMID: 10776834]
[62]
Campbell LK, Baker DE, Campbell RK. Miglitol: assessment of its role in the treatment of patients with diabetes mellitus. Ann Pharmacother 2000; 34(11): 1291-301.
[http://dx.doi.org/10.1345/aph.19269] [PMID: 11098345]
[63]
Joubert PH, Venter HL, Foukaridis GN. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism? Br J Clin Pharmacol 1990; 30(3): 391-6.
[http://dx.doi.org/10.1111/j.1365-2125.1990.tb03789.x] [PMID: 2223417]
[64]
Lee A, Patrick P, Wishart J, Horowitz M, Morley JE. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 2002; 4(5): 329-35.
[http://dx.doi.org/10.1046/j.1463-1326.2002.00219.x] [PMID: 12190996]
[65]
Johnston PS, Coniff RF, Hoogwerf BJ, Santiago JV, Pi-Sunyer FX, Krol A. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 1994; 17(1): 20-9.
[http://dx.doi.org/10.2337/diacare.17.1.20] [PMID: 8112185]
[66]
Segal P, Feig PU, Schernthaner G, et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 1997; 20(5): 687-91.
[http://dx.doi.org/10.2337/diacare.20.5.687] [PMID: 9135927]
[67]
Bradley R. Evaluation of Quercetin in Type 2 Diabetes: Impact on Glucose Tolerance and Postprandial Endothelial Function [homepage on the Internet]. 2015. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01839344?term=alpha+glucosidase+inhibitors&type=Intr&cond=Type2+Diabetes&draw=3&rank=12
[68]
Lavanya G, Venkatapathy K, Magesh CJ, Ramanathan M, Jayasudha R. The first target specific, highly diastereoselective synthesis, design and characterization of pyranoquinolinyl acrylic acid diastereomers as potential α-glucosidase inhibitors. Bioorg Chem 2019; 84: 125-36.
[http://dx.doi.org/10.1016/j.bioorg.2018.11.026] [PMID: 30500522]
[69]
Kim HH, Kang YR, Choi HY, et al. Postprandial anti-hyperglycemic effect of vitamin B6 (pyridoxine) administration in healthy individuals. Food Sci Biotechnol 2019; 28(3): 907-11.
[http://dx.doi.org/10.1007/s10068-018-0534-7] [PMID: 31093449]
[70]
Wan JX, Lim G, Lee J, et al. Inhibitory effect of phloroglucinol on α-glucosidase: Kinetics and molecular dynamics simulation integration study. Int J Biol Macromol 2019; 124: 771-9.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.11.268] [PMID: 30503787]
[71]
Saeedi M, Mohammadi-Khanaposhtani M, Pourrabia P, et al. Design and synthesis of novel quinazolinone-1,2,3-triazole hybrids as new anti-diabetic agents: In vitro α-glucosidase inhibition, kinetic, and docking study. Bioorg Chem 2019; 83: 161-9.
[http://dx.doi.org/10.1016/j.bioorg.2018.10.023] [PMID: 30366316]
[72]
Zaharudin N, Staerk D, Dragsted LO. Inhibition of α-glucosidase activity by selected edible seaweeds and fucoxanthin. Food Chem 2019; 270: 481-6.
[http://dx.doi.org/10.1016/j.foodchem.2018.07.142] [PMID: 30174076]
[73]
Zhang LL, Han L, Yang SY, Meng XM, Ma WF, Wang M. The mechanism of interactions between flavan-3-ols against a-glucosidase and their in vivo antihyperglycemic effects. Bioorg Chem 2019; 85: 364-72.
[http://dx.doi.org/10.1016/j.bioorg.2018.12.037] [PMID: 30658236]
[74]
Ma LF, Yan JJ, Lang HY, et al. Bioassay-guided isolation of lanostane-type triterpenoids as α-glucosidase inhibitors from Ganoderma hainanense. Phytochem Lett 2019; 29: 154-9.
[http://dx.doi.org/10.1016/j.phytol.2018.12.007]
[75]
Vinodhini S, Rajeswari VD. Exploring the antidiabetic and anti-obesity properties of Samanea saman through in vitro and in vivo approaches. J Cell Biochem 2018; 120: 1539-49.
[http://dx.doi.org/10.1002/jcb.27385] [PMID: 30378154]
[76]
Mohamed EA, Ahmad M, Ang LF, Asmawi MZ, Yam MF. Evaluation of α-glucosidase inhibitory effect of 50% ethanolic standardized extract of Orthosiphon stamineus benth in normal and streptozotocin-induced diabetic rats. Evid Based Complement Alternat Med 2015; 2015754931
[http://dx.doi.org/10.1155/2015/754931] [PMID: 26649063]
[77]
Priscilla DH, Roy D, Suresh A, Kumar V, Thirumurugan K. Naringenin inhibits α-glucosidase activity: a promising strategy for the regulation of postprandial hyperglycemia in high fat diet fed streptozotocin induced diabetic rats. Chem Biol Interact 2014; 210: 77-85.
[http://dx.doi.org/10.1016/j.cbi.2013.12.014] [PMID: 24412302]
[78]
Aslam H, Khan AU, Naureen H, Ali F, Ullah F, Sadiq A. Potential application of Conyza canadensis (L) Cronquist in the management of diabetes: In vitro and in vivo evaluation. Trop J Pharm Res 2018; 17: 1287-93.
[http://dx.doi.org/10.4314/tjpr.v17i7.9]
[79]
Antu KA, Riya MP, Mishra A, et al. Antidiabetic property of Symplocos cochinchinensis is mediated by inhibition of alpha glucosidase and enhanced insulin sensitivity. PLoS One 2014; 9(9)e105829
[http://dx.doi.org/10.1371/journal.pone.0105829] [PMID: 25184241]
[80]
Mohamed Sham Shihabudeen H, Hansi Priscilla D, Thirumurugan K. Cinnamon extract inhibits α-glucosidase activity and dampens postprandial glucose excursion in diabetic rats. Nutr Metab (Lond) 2011; 8(1): 46.
[http://dx.doi.org/10.1186/1743-7075-8-46] [PMID: 21711570]
[81]
Nasma A, Aishath N, Azilah A, Sulaiman AZ. Optimization of vitexin and isovitexin compounds extracted from dried Mas Cotek leaves using one-factor-at-a-time (OFAT) approach in aqueous extraction. Int Food Res J 2018; 25: 2560-71.
[82]
Lee SH, Park MH, Heo SJ, et al. Dieckol isolated from Ecklonia cava inhibits α-glucosidase and α-amylase in vitro and alleviates postprandial hyperglycemia in streptozotocin-induced diabetic mice. Food Chem Toxicol 2010; 48(10): 2633-7.
[http://dx.doi.org/10.1016/j.fct.2010.06.032] [PMID: 20600532]
[83]
Liu S, Li D, Huang B, Chen Y, Lu X, Wang Y. Inhibition of pancreatic lipase, α-glucosidase, α-amylase, and hypolipidemic effects of the total flavonoids from Nelumbo nucifera leaves. J Ethnopharmacol 2013; 149(1): 263-9.
[http://dx.doi.org/10.1016/j.jep.2013.06.034] [PMID: 23811214]
[84]
Tran HH, Nguyen MC, Le HT, et al. Inhibitors of α-glucosidase and α-amylase from Cyperus rotundus. Pharm Biol 2014; 52(1): 74-7.
[http://dx.doi.org/10.3109/13880209.2013.814692] [PMID: 24044731]
[85]
Liu F, Ma H, Wang G, et al. Phenolics from Eugenia jambolana seeds with advanced glycation endproduct formation and alpha-glucosidase inhibitory activities. Food Funct 2018; 9(8): 4246-54.
[http://dx.doi.org/10.1039/C8FO00583D] [PMID: 30009284]
[86]
Rani GRMASC, Viswanadham M, Thupurani MK. Antidiabetic activity of the compounds isolated from rhus mysorensis plant extract. IOSR J Biotechnol Biochem 2017; 3: 37-42.
[http://dx.doi.org/10.9790/264X-03033742]
[87]
Rynjah CV, Devi NN, Khongthaw N, Syiem D, Majaw S. Evaluation of the antidiabetic property of aqueous leaves extract of Zanthoxylum armatum DC. using in vivo and in vitro approaches. J Tradit Complement Med 2017; 8(1): 134-40.
[http://dx.doi.org/10.1016/j.jtcme.2017.04.007] [PMID: 29322001]
[88]
Agawane SB, Gupta VS, Kulkarni MJ, Bhattacharya AK, Koratkar SS. Chemo-biological evaluation of antidiabetic activity of Mentha arvensis L. and it’s role in inhibition of advanced glycation end products. J Ayurveda Integr Med 2018; 2: 5-9.
[PMID: 29398410]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 23
Year: 2019
Published on: 16 July, 2019
Page: [2510 - 2525]
Pages: 16
DOI: 10.2174/1381612825666190717104547
Price: $65

Article Metrics

PDF: 47
HTML: 14
EPUB: 1
PRC: 1